Literature DB >> 23166626

Elevated bile acids in newborns with Biliary Atresia (BA).

Kejun Zhou1, Na Lin, Yongtao Xiao, Yang Wang, Jie Wen, Gang-Ming Zou, Xuefan Gu, Wei Cai.   

Abstract

Biliary Atresia (BA), a result from inflammatory destruction of the intrahepatic and extrahepatic bile ducts, is a severe hepatobiliary disorder unique to infancy. Early diagnosis and Kasai operation greatly improve the outcome of BA patients, which encourages the development of early screening methods. Using HPLC coupled tandem mass spectrometry, we detected primary bile acids content in dried blood spots obtained from 8 BA infants, 17 neonatal jaundice and 292 comparison infants at 3-4 days of life. Taurocholate (TC) was significantly elevated in biliary atresia infants (0.98 ± 0.62 µmol/L) compared to neonatal jaundice (0.47 ± 0.30 µmol/L) and comparison infants (0.43 ± 0.40 µmol/L), with p=0.0231 and p=0.0016 respectively. The area under receiver operating characteristic (ROC) curve for TC to discriminate BA and comparison infants was 0.82 (95% confidence interval: 0.72-0.92). A cutoff of 0.63 µmol/L produced a sensitivity of 79.1% and specificity of 62.5%. The concentrations of total bile acids were also raised significantly in BA compared to comparison infants (6.62 ± 3.89 µmol/L vs 3.81 ± 3.06 µmol/L, p=0.0162), with the area under ROC curve of 0.75 (95% confidence interval: 0.61-0.89). No significant difference was found between the bile acids of neonatal jaundice and that of comparison infants. The early increase of bile acids indicates the presentation of BA in the immediate newborn period and the possibility of TC as newborn screening marker.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23166626      PMCID: PMC3498146          DOI: 10.1371/journal.pone.0049270

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Biliary atresia (BA) is the most significant life-threatening hepatobiliary disorder in children which results from destructive inflammatory process of both intrahepatic and extrahepatic bile ducts [1], [2]. If untreated, progressive liver cirrhosis leads to death by 2 years of age. Clinical features of BA include jaundice, pale stools and dark urine, shown at or soon after birth with normal birth weights. The etiology of BA is largely unknown. Diagnosis of BA is still difficult and operative cholangiography to visualize the biliary tract is still the golden standard for the diagnosis [2]. Kasai portoenterostomy is the first choice of treatment and good results depend on early diagnosis and operation [3], [4], [5]. Since the use of the infant stool color card to screen BA in Taiwan, BA patients have been diagnosed earlier and the outcomes have been improved remarkably [6]. However this screening method is greatly affected by parents' subjectivity. Because of the importance of early diagnosis and treatment, a great deal of efforts have been made to develop early detection methods for BA. For instance, conjugated bilirubin in plasma measured at 6–10 days is a reliable marker for neonatal liver disease [7]. Furthermore, elevated direct/conjugated bilirubin levels were found shortly after birth (within 24–72 hours) in BA infants [8]. Unfortunately, conjugated bilirubin cannot be detected in dried blood spots because of its light sensitivity. Bile acids, as other important makers related with liver injury and cholestasis , are widely investigated to screen or discriminate cholestasis diseases, including BA [9], intrahepatic cholestasis of pregnancy [10] and bile acid synthesis defects [11]. With the widespread application of tandem mass spectrometry, this technology was used to detect bile acids in dried blood spots [12], [13], [14]. To evaluate if bile acids can be used as early screening marker for BA, we detected the six primary bile acids in dried blood spots of BA at 3–4 days after birth.

Methods

BA, neonatal jaundice, and comparison group

BA and neonatal jaundice cases were identified from Xin Hua Hospital, Shanghai, China. BA cases were diagnosed by cholangiography. All the neonatal jaundice infants shown jaundice within 4 days after birth. Dried blood spots originally collected for screening of phenylketonuria were used for this study. All the dried blood spots were stored at −20°C after phenylketonuria screening. Anonymized screening cards of the same month were randomly selected to provide a comparison group of each BA card. Ethical approval was obtained from the ethics committee of Xin Hua Hospital. Written informed consent was obtained from parents of all BA and neonatal jaundice infants and oral consent was obtained from parents of all comparison infants. Serum total and direct bilirubin when these patients were hospitalized were listed in Table S1.

Calibrators and Sample analysis

Stock solutions of 500 µmol/L of primary bile acids (cholic acid : CA, glycocholate : GC, taurocholate : TC, chenodeoxycholate : CDC, glycochenodeoxycholate : GCDC, taurochenodeoxycholate : TCDC) were used to prepare calibrators. Whole blood with a hematocrit of 55% active carbon desalted serum was spiked with proper amount of stock solution to achieve final concentrations of 20, 5.0, 1.0, 0.5, 0.1, 0.05 and 0 µmol/L bile acids. Twenty-five micro liter of spiked whole blood was used for the preparation of blood spot standards on filter paper. Calibrators were stored at −20°C. Concentrations of the six primary bile acids were detected in dried blood spots with an API 4000 MS coupled with a HPLC system according to the method described by Janzen et al with small modifications[13]. Three millimeter discs were punched and incubated in 150 µl methanol with 0.5 µmol/L cholic-2,2,4,4-d 4 acid (d 4 –CA, internal standard) for 30 min. Ten micro liter of supernatant was injected and separation was achieved using a Luna C18 column of 50×2.0 mm, 3 µmol/L, which was protected by a C18 4×2.0 mm Precolumn from Phenomex (Aschaffenburg, Germany). Data acquisition was performed using Analyst 1.5 software from Applied Biosystems. Analytical settings and limit of quantification for the six primary bile acids were listed in Table S2. Total bile acid concentration was calculated from sum of the six bile acids [15].

Statistical analysis

The data of bile acids were tested for normal distribution using the Shapiro-Wilk test before calculation of differences. Normally distributed data was analyzed using one-way ANOVA followed by a Post Hoc Dunnett Test. Non-normally distributed data was analyzed using the Wilcox test or the Kruskal test. A p-value of <0.05 was considered statistically significant. Receiver operating characteristic (ROC) curves were plotted to compare the screening ability of these bile acids. All the analysis was carried out on the freely available software R with corresponding packages. ROC curves and box-plots of these bile acids were drawn by SPSS version 19.0.

Results

Dried blood spots from 292 comparison infants, 17 neonatal jaundice and 8 biliary atresia infants were enrolled in this study. Six primary bile acids (CA, GC, TC, CDC, GCDC, and TCDC) were measured in the dried blood spots with API 4000 tandem MS. Figure S1 presents a representative LC-MS/MS chromatogram of bile acids in dried blood spots from BA. The concentrations of conjugated primary bile acids were much higher than the un-conjugated ones. The CA and CDC concentrations in most cases were under the quantification limits. Hence, data of these two bile acids was not analyzed in the following study. The data of conjugated primary bile acids in comparison group was tested for normal distribution using the Shapiro-Wilk Test initially. Because none of the data was normally distributed (data not shown), the Wilcox test was used to analyze the differences among BA, neonatal jaundice and comparison infants. Concentrations of the four conjugated bile acids and total bile acids were significantly higher in BA than comparison infants (table 1). However, great overlaps existed between the two groups (Figure 1 and 2). TC was most significantly elevated in BA infants (0.98±0.62 µmol/L) compared to neonatal jaundice (0.47±0.30 µmol/L) and comparison infants (0.43±0.40 µmol/L), with p = 0.0231 and p = 0.0016 respectively. The means of GC and GCDC were higher in BA than in neonatal jaundice infants with marginal significance (GC: 2.71±2.26 µmol/L vs 1.31±1.11 µmol/L, p = 0.0664; GCDC: 0.94±0.55 µmol/L vs 0.63±0.54 µmol/L, p = 0.0967). No significant difference was found between neonatal jaundice and the comparison infants except a minor increase of TCDC (1.82±1.47 µmol/L vs 1.34±1.29 µmol/L, p = 0.0591).
Table 1

Bile acids concentrations (mean±SD) in dried blood spots of BA, neonatal jaundice and comparison infants.

VariablesComparison group (n = 292)Jaundice group (n = 17)BA group (n = 8)P value
Comparison vs JaundiceComparison vs BAJaundice vs BA
GC (µmol/L)1.24±1.401.31±1.112.71±2.260.2551 0.0139 0.0664
GCDC (µmol/L)0.65±0.660.63±0.540.94±0.550.7747 0.0487 0.0967
TC (µmol/L)0.43±0.400.47±0.300.98±0.620.2409 0.0016 0.0231
TCDC (µmol/L)1.34±1.291.82±1.471.85±0.820.05906 0.0304 0.5216
Total bile Acids (µmol/L)3.81±3.064.36±2.646.62±3.890.2787 0.0162 0.1299
Figure 1

Boxplots of GC (A), GCDC (B), TC (C) and TCDC (D) in dried blood spots of biliary atresia (n = 8), neonatal jaundice (n = 17) and comparison infants (n = 292).

The concentrations of GC, GCDC, TC, and TCDC in BA were significantly higher than those of comparison infants (p<0.05). TC was also significantly elevated in BA compared to neonatal jaundice. No significant difference was observed between neonatal jaundice and comparison infants. BA: biliary atresia infants, Jaun: neonatal jaundice infants, NC: comparison infants.

Figure 2

Boxplot of total bile acids in dried blood spots of biliary atresia (n = 8), neonatal jaundice (n = 17) and comparison infants (n = 292).

The level of total bile acids in BA was raised significantly compared to comparison infants, with p = 0.0162. BA: biliary atresia infants, Jaun: neonatal jaundice infants, NC: comparison infants.

Boxplots of GC (A), GCDC (B), TC (C) and TCDC (D) in dried blood spots of biliary atresia (n = 8), neonatal jaundice (n = 17) and comparison infants (n = 292).

The concentrations of GC, GCDC, TC, and TCDC in BA were significantly higher than those of comparison infants (p<0.05). TC was also significantly elevated in BA compared to neonatal jaundice. No significant difference was observed between neonatal jaundice and comparison infants. BA: biliary atresia infants, Jaun: neonatal jaundice infants, NC: comparison infants.

Boxplot of total bile acids in dried blood spots of biliary atresia (n = 8), neonatal jaundice (n = 17) and comparison infants (n = 292).

The level of total bile acids in BA was raised significantly compared to comparison infants, with p = 0.0162. BA: biliary atresia infants, Jaun: neonatal jaundice infants, NC: comparison infants. Figure 3 shows receiver operating characteristic curves for TC and total bile acids to discriminate BA and comparison infants. The area under the ROC curve for TC was 0.82 ( 95% confidence interval: 0.72–0.92) which was significantly larger than total bile acids (with the area under ROC curve of 0.75, 95% confidence interval: 0.61–0.89) with p = 0.01976. Besides, the sensitivity and specificity values for various TC cutoff levels were calculated (Table 2). A cutoff of 0.63 µmol/L produced a sensitivity of 79.1%, specificity of 62.5%.
Figure 3

Receiver operating charactristic curves to discriminate BA and comparison infants for concentrations of TC and total bile acids.

The area under the curve was 0.82 (95% confidence interval: 0.72–0.92) for TC and 0.75 (95% confidence interval: 0.61–0.89) respectively, with p = 0.01976.

Table 2

Sensitivity and specificity of TC concentration in prediction of BA.

Cutoff% Sensitivity (95% CI)% Specificity (95% CI)
0.798586.6(82.5–90.1)50(12.5–87.5)
0.63 79.1(74.3–83.2) 62.5(25–87.5)
0.572.3(67.5–77.4)75(37.5–100)
0.473568.8(63.7–74.0)87.5(62.5–100)
0.422563.4(58.2–68.5)100(100–100)

Receiver operating charactristic curves to discriminate BA and comparison infants for concentrations of TC and total bile acids.

The area under the curve was 0.82 (95% confidence interval: 0.72–0.92) for TC and 0.75 (95% confidence interval: 0.61–0.89) respectively, with p = 0.01976. To analyze the difference among different storage time, different gestational weeks and different genders, the Kruskal test was also carried out. The conjugated primary bile acids show no difference between different storage time, gestation weeks and genders (data not shown).

Discussion

Biliary atresia is the most common cause of neonatal cholestasis and 40–50% of liver transplantation in children is caused by this disease [16]. Early intervention of Kasai portoenterostomy is very important for BA patients. When the surgery is performed before the age of 60 days, the success rate of establishing biliary drainage is higher than those performed later [17] and the need for liver transplantations in infancy and childhood is greatly reduced [5]. In this study, we evaluated the six primary bile acids in dried blood spots of BA, neonatal jaundice and comparison infants obtained 3–4 days after birth. All the conjugated primary bile acids have already increased in BA newborns at 3–4 days of life which echoes the report that all these bile acids were elevated significantly in BA infants 7–10 days after birth [15]. The results indicated that BA was present in the immediate newborn period or late pregnancy. This is also supported by a case report by Toubi et al., where a BA infants with disappeared gallbladder at age of 11 days was used to have normal gallbladder at the gestational age of 24 weeks [18]. In our study, the increase of TC and GC was higher than TCDC and GCDC in early life of BA, while Mills et al. found that the later 2 bile acids increased more significant in cholestatic children at age of 3 weeks to 8 month [19]. These findings may indicate that the liver damage has already begun but is still mild in BA infants within 3–4 days of age as greater rise of TCDC and GCDC meant severe liver damage [20]. Furthermore, TC was found positively correlated with MCP-1, an HSC-responsive chemokine, in cholestatic rats and in cystic fibrosis liver disease [21]. The early elevation of TC may indicate the early occurrence of fibrosis in BA patients. According to previous research, two of the most promising screening methods for BA yet are early measurement of serum conjugated bilirubin and usage of stool color cards. In the test of serum conjugated bilirubin at 6–10 days after birth, the sensitivity and specificity reach 100% and 99.6% respectively [7]. However, due to the light sensitivity of bilirubin, it is unsuitable to detect in dried blood spots, which are easy to obtain and deliver for newborn screening. Another method, the stool color card is widely used in Taiwan to screen BA patients. The sensitivity of this method was 97.1% in 2005 [22]. However the onset of pale stool in a large amount of cases usually occurs later than 30 days of age, which may delay the diagnosis and affect the outcome of treatment. Measurement of TC in dried blood spots by LC-MS/MS may be suitable for newborn screening due to the stability in dried blood spots and relatively simple detection technique, although the sensitivity and specificity are not as good as serum conjugated bilirubin and the stool color card. Furthermore, considering the effect of diurnal variations on the level of bile acids in blood [23], the detecting accuracy may increase if all blood spots were taken forenoon. After all, the elevated concentrations of TC and other bile acids in dried blood spots from BA infants have already indicted the potential screening strategy for the future study. Interestingly, no significant difference of bile acids was observed between neonatal jaundice and comparison infants. This result was understandable. It is well known that genetic and environmental factors influence neonatal jaundice, such as ABO incompatibility, breastfeeding and the method of delivery [24]. The infants with neonatal jaundice enrolled in this study have unconjugated hyperbilirubinemia which are unrelated with hepatobiliary disease. The main shortage of this study is the small sample size of BA. Because of the scarcity of the disease, insufficient therapeutic effects and low levels of cooperation among pediatric hospitals in China, it is hard to obtain screening dried blood spots from BA patients. Furthermore, the detection methods need to be improved, which include but are not limited to the introduction of UPLC, more sensitive MS and proper sample pretreatment methods. In conclusion, bile acids were elevated in BA infants at 3–4 days of age indicates the immediate occurrence of the disease at birth. The measurement of bile acids, especially TC, in dried blood spots from newborns could be the potential screening strategy for early detection of BA. Serum total bilirubin and direct bilirubin in patients with biliary atresia and neonatal jaundice. (DOCX) Click here for additional data file. Analytical settings and limit of quantification of the primary bile acids in dried blood spots. (DOCX) Click here for additional data file. A representative chromatogram of bile acids in a dried blood spot from a biliary atresia infant with 0.5 µM d4-CA. The concentrations of conjugated primary bile acids were much higher than unconjugated ones. Unconjugated bile acids, CA and CDC, were under the quantification limits. (DOCX) Click here for additional data file.
  24 in total

1.  The serum trihydroxy-dihydroxy bile acid ratio in liver and biliary tract disease.

Authors:  J B CAREY
Journal:  J Clin Invest       Date:  1958-11       Impact factor: 14.808

2.  Screening of newborn infants for cholestatic hepatobiliary disease with tandem mass spectrometry.

Authors:  I Mushtaq; S Logan; M Morris; A W Johnson; A M Wade; D Kelly; P T Clayton
Journal:  BMJ       Date:  1999-08-21

3.  Is breastfeeding really favoring early neonatal jaundice?

Authors:  G Bertini; C Dani; M Tronchin; F F Rubaltelli
Journal:  Pediatrics       Date:  2001-03       Impact factor: 7.124

4.  Differential diagnosis in patients with suspected bile acid synthesis defects.

Authors:  Dorothea Haas; Hongying Gan-Schreier; Claus-Dieter Langhans; Tilman Rohrer; Guido Engelmann; Maura Heverin; David W Russell; Peter T Clayton; Georg F Hoffmann; Jürgen G Okun
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

5.  Late referral for biliary atresia--missed opportunities for effective surgery.

Authors:  G Mieli-Vergani; E R Howard; B Portman; A P Mowat
Journal:  Lancet       Date:  1989-02-25       Impact factor: 79.321

6.  A method for the quantitation of conjugated bile acids in dried blood spots using electrospray ionization-mass spectrometry.

Authors:  K A Mills; I Mushtaq; A W Johnson; P D Whitfield; P T Clayton
Journal:  Pediatr Res       Date:  1998-03       Impact factor: 3.756

7.  Population screening for neonatal liver disease: potential for a community-based programme.

Authors:  J E Powell; S Keffler; D A Kelly; A Green
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

8.  Prolonged neonatal jaundice and the diagnosis of biliary atresia: a single-center analysis of trends in age at diagnosis and outcomes.

Authors:  Sharad I Wadhwani; Yumirle P Turmelle; Rosemary Nagy; Jeffrey Lowell; Patrick Dillon; Ross W Shepherd
Journal:  Pediatrics       Date:  2008-04-28       Impact factor: 7.124

9.  Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment.

Authors:  Grant A Ramm; Ross W Shepherd; Anita C Hoskins; Sonia A Greco; Agnieszka D Ney; Tamara N Pereira; Kim R Bridle; James D Doecke; Peter J Meikle; Bruno Turlin; Peter J Lewindon
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

10.  Universal screening for biliary atresia using an infant stool color card in Taiwan.

Authors:  Cheng-Hui Hsiao; Mei-Hwei Chang; Huey-Ling Chen; Hung-Chang Lee; Tzee-Chung Wu; Chieh-Chung Lin; Yao-Jong Yang; An-Chyi Chen; Mao-Meng Tiao; Beng-Huat Lau; Chia-Hsiang Chu; Ming-Wei Lai
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

View more
  11 in total

1.  Identification of a plant isoflavonoid that causes biliary atresia.

Authors:  Kristin Lorent; Weilong Gong; Kyung A Koo; Orith Waisbourd-Zinman; Sara Karjoo; Xiao Zhao; Ian Sealy; Ross N Kettleborough; Derek L Stemple; Peter A Windsor; Stephen J Whittaker; John R Porter; Rebecca G Wells; Michael Pack
Journal:  Sci Transl Med       Date:  2015-05-06       Impact factor: 17.956

2.  Referral Patterns and Factors Influencing Age at Admission of Infants with Cholestasis in India.

Authors:  Gopinathan Mathiyazhagan; Barath Jagadisan
Journal:  Indian J Pediatr       Date:  2017-04-11       Impact factor: 1.967

3.  Comprehensive Analysis of Gut Microbiota and Fecal Bile Acid Profiles in Children With Biliary Atresia.

Authors:  Ting Yang; Shen Yang; Jiawei Zhao; Peize Wang; Siqi Li; Yuyan Jin; Zhaozhou Liu; Xinyue Zhang; Yanan Zhang; Yong Zhao; Junmin Liao; Shuangshuang Li; Kaiyun Hua; Yichao Gu; Dingding Wang; Jinshi Huang
Journal:  Front Cell Infect Microbiol       Date:  2022-06-17       Impact factor: 6.073

Review 4.  Biliary atresia and congenital disorders of the extrahepatic bile ducts.

Authors:  Ali Islek; Gokhan Tumgor
Journal:  World J Gastrointest Pharmacol Ther       Date:  2022-07-05

Review 5.  Diagnostic Tools for Early Detection of Biliary Atresia: Is a Newborn Screen Attainable?

Authors:  Michelle M Corrado; Cara L Mack
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-01-24

6.  Comparison between cystic biliary atresia and choledochal cyst: a clinical controlled study.

Authors:  Pu Yu; Ning Dong; Yong Kang Pan; Long Li
Journal:  Pediatr Surg Int       Date:  2021-09-15       Impact factor: 1.827

7.  Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome.

Authors:  Dongying Zhao; Lianshu Han; Zhengjuan He; Jun Zhang; Yongjun Zhang
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  The toxin biliatresone causes mouse extrahepatic cholangiocyte damage and fibrosis through decreased glutathione and SOX17.

Authors:  Orith Waisbourd-Zinman; Hong Koh; Shannon Tsai; Pierre-Marie Lavrut; Christine Dang; Xiao Zhao; Michael Pack; Jeff Cave; Mark Hawes; Kyung A Koo; John R Porter; Rebecca G Wells
Journal:  Hepatology       Date:  2016-05-20       Impact factor: 17.425

9.  Coordinated development of the mouse extrahepatic bile duct: Implications for neonatal susceptibility to biliary injury.

Authors:  Gauri Khandekar; Jessica Llewellyn; Alyssa Kriegermeier; Orith Waisbourd-Zinman; Nicolette Johnson; Yu Du; Roquibat Giwa; Xiao Liu; Tatiana Kisseleva; Pierre A Russo; Neil D Theise; Rebecca G Wells
Journal:  J Hepatol       Date:  2019-09-25       Impact factor: 30.083

10.  Development and validation of bile acid profile-based scoring system for identification of biliary atresia: a prospective study.

Authors:  Dongying Zhao; Kejun Zhou; Yan Chen; Wei Xie; Yongjun Zhang
Journal:  BMC Pediatr       Date:  2020-05-27       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.